Theriva Biologics, Inc. (TOVX) - Form 8-K Summary
Business Context and Reporting Period
Theriva Biologics, Inc., a Nevada corporation, filed this Current Report on Form 8-K on May 5, 2026. The filing serves to disclose the issuance of a press release containing financial information for the quarter ended March 31, 2026. The company is listed on the NYSE American under the symbol TOVX and identifies as an emerging growth company.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document explicitly states that the financial details for the quarter ended March 31, 2026, are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the text of this 8-K.
Material Changes
No material changes versus the prior comparable period are detailed in the text of this filing. The report functions solely as a notification of the press release issuance; comparative financial analysis is absent from the provided content.
Guidance, Outlook, and Risks
The filing includes standard legal disclaimers stating that the information in Item 2.02 and the attached press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other SEC filings. No specific guidance, management commentary, risks, or contingencies are described in the text of this 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 5, 2026) for actual financial figures for the quarter ended March 31, 2026.
- Verify the company's status as an emerging growth company and any election regarding extended transition periods for accounting standards.
- Confirm the trading status of Common Stock (TOVX) on the NYSE American.
- Check subsequent filings for the full financial statements if the press release contains only summarized data.